A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

被引：0

作者：

Kelly, K

Mikhaeel-Kamel, N

Pan, ZX

Murphy, J

Prindiville, S

Bunn, PA

机构：

[1] Univ Colorado, Hlth Sci Ctr, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA

[2] Univ Colorado, Ctr Canc, Lung Canc Program, Denver, CO 80262 USA

[3] Univ Colorado, Ctr Canc, Dept Prevent Med & Biostat, Denver, CO 80262 USA

来源：

CLINICAL CANCER RESEARCH | 2000年 / 6卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

引用

页码：3474 / 3479

页数：6

共 50 条

[1] A phase I trial of paclitaxel, carboplatin, and gemcitabine in advanced non-small cell lung cancer
Kelly, K
Prindiville, S
Bunn, PA
[J]. SEMINARS IN ONCOLOGY, 1999, 26 (01) : 74 - 74
[2] A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
Kelly, K
Pan, ZX
Murphy, J
Huffman, DH
Bunn, PA
[J]. CLINICAL CANCER RESEARCH, 1997, 3 (07) : 1117 - 1123
[3] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
Domine, M
Gomez, RG
Firvida, J
Delgado, J
Estevez, L
Docampo, LI
Leon, A
Pachon, V
Casado, V
Lobo, F
[J]. LUNG CANCER, 2005, 49 : S242 - S242
[4] Randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine in untreated advanced non-small cell lung cancer
Kinoshita, A.
Fukuda, M.
Nagashima, S.
Fukuda, M.
Takatani, H.
Nakano, H.
Nakamura, Y.
Oka, M.
Soda, H.
Kohno, S.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 382 - 382
[5] Paclitaxel and carboplatin in combination with gemcitabine: A phase I-II trial in patients with advanced non-small-cell lung cancer
Favaretto, A
Ceresoli, GL
Paccagnella, A
Barbieri, F
Bearz, A
Ghiotto, C
Oniga, F
Schiavon, S
Frustaci, S
Villa, E
[J]. ANNALS OF ONCOLOGY, 2000, 11 (11) : 1421 - 1426
[6] Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial
Masotti, A
Zannini, G
Gentile, A
Morandini, G
[J]. LUNG CANCER, 2002, 36 (01) : 99 - 103
[7] Phase I/II trial of weekly docetaxel and carboplatin in previously untreated patients with advanced non-small cell lung cancer
Walsh, W
Gordon, J
Merolli, R
Seidler, C
Kasturi, V
Finn, T
Liu, Q
Strauss, G
[J]. LUNG CANCER, 2004, 46 : S63 - S63
[8] Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
Kim, Han Jo
Kim, Kyoung Ha
Yun, Jina
Kim, Se Hyung
Kim, Hyun Jung
Lee, Sang-Cheol
Bae, Sang Byung
Kim, Chan Kyu
Lee, Nam Su
Lee, Kyu Taek
Kim, Do-Jin
Park, Seong-Kyu
Won, Jong-Ho
Hong, Dae Sik
Park, Hee Sook
[J]. CANCER RESEARCH AND TREATMENT, 2011, 43 (01): : 19 - 23
[9] Paclitaxel and Carboplatin in combination with Gemcitabine (PCG): A phase I-II trial in non-small cell lung cancer (NSCLC)
Favaretto, A
Paccagnella, A
Tumolo, S
Barbieri, F
Ceresoli, G
Gulisano, M
Oniga, F
Bearz, A
Fiorentino, MV
[J]. ANNALS OF ONCOLOGY, 1998, 9 : 91 - 91
[10] Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer
Burris, HA
Hainsworth, JD
Erland, JB
Morrissey, LH
Kalman, LA
Hon, JK
Scullin, DC
Smith, SW
Greco, FA
[J]. SEMINARS IN ONCOLOGY, 2000, 27 (01) : 9 - 13

← 1 2 3 4 5 →